Karyopharm Therapeutics Profit Margin

The latest profit margin for KPTI is -153.28% as of June 2026. That compares with -96.53% in the prior-year period — down 58.8% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Karyopharm Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KPTI's profit margin moved from -96.53% to -153.28% — a 58.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Karyopharm Therapeutics's valuation or profitability profile.

Against Healthcare companies, KPTI currently prints -153.28% for profit margin, while the sector average sits near 13.89%. That is roughly 1203.3% below the sector mean. Large gaps often invite a closer look at Karyopharm Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Karyopharm Therapeutics converts resources into returns. At -153.28%, KPTI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -96.53% in the prior-year period — down 58.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting KPTI's profit margin (-153.28%), review year-over-year change from -96.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.